Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in neoadjuvant TNBC
NCT05862610Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of trilaciclib in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05862610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862610.